131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat

Inclusion Criteria

• Patients must be > 24 months and < 30 years of age when registered on study.
• Patients must have relapsed neuroblastoma, refractory neuroblastoma that had less than a partial response to standard treatment or persistent neuroblastoma that had at least a partial response to frontline therapy frontline therapy with > 3 residual lesions on end-induction MIBG scan.
• Patients must have evidence of MIBG uptake into tumor at ≥ one site within 4 weeks prior to entry on study and subsequent to any intervening therapy.
• Patients must have adequate heart, kidney, liver and bone marrow function. Patients who have bone marrow disease must still have adequate bone marrow function to enter the study.
• Patients must have a dose of unpurged peripheral blood stem cells is 2.0 x 106 viable CD34+ cells/kg available.

Exclusion Criteria

• They have had previous I-131 MIBG therapy
• They have other medical problems that could get much worse with this treatment.
• They are pregnant or breast feeding.
• They have a history of a venous or arterial thrombosis that was not associated to a central line.
• They have active infections such as hepatitis or fungal infections.
• They have active diarrhea.
• They have had an allogeneic stem cell transplant (received stem cell from someone else)
• They can't cooperate with the special precautions that are needed for this trial.